Evidence map›Paper›PMID 34244548›Full record

ArticleScientific reports2021

Metallomic profile in non-cirrhotic hepatocellular carcinoma supports a phenomenon of metal metabolism adaptation in tumor cells.

Luis Cano, Stéphane Bertani, Marie-Laure Island, Juan Pablo Cerapio, Eloy Ruiz, Pascal Pineau, Valérie Monbet, Karim Boudjema, Luis Taxa, Sandro Casavilca-Zambrano and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Carcinogenic effect of arsenic in digestive cancers: a systematic review.Environmental health : a global access science source · 2023
    Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Luis CanoINSERM UMR 1241, Nutrition, Metabolisms and Cancer Institute (NUMECAN), AEM2 Platform, INRAE, CHU Pontchaillou, University of Rennes, 2 Rue Henri le Guilloux, 35033, Rennes, France.
Stéphane BertaniIRD, UPS, UMR152 Pharmadev, Université de Toulouse, Toulouse, France.
Marie-Laure IslandINSERM UMR 1241, Nutrition, Metabolisms and Cancer Institute (NUMECAN), AEM2 Platform, INRAE, CHU Pontchaillou, University of Rennes, 2 Rue Henri le Guilloux, 35033, Rennes, France.
Juan Pablo CerapioCentre de Recherches en Cancérologie de Toulouse, INSERM, UPS, UMR 1037, CNRS, ERL, Université de Toulouse, 5294, Toulouse, France.
Eloy RuizDepartamento de Cirugía Abdominal, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Pascal PineauUnité Organisation Nucléaire et Oncogenèse, INSERM, U993, Institut Pasteur, Paris, France.
Valérie MonbetIRMAR, INRIA, Université de Rennes, Rennes, France.
Karim BoudjemaService de Chirurgie Hépatobiliaire et Digestive, CHU Rennes, Université de Rennes, Rennes, France.
Luis TaxaDepartamento de Patología, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Sandro Casavilca-ZambranoDepartamento de Patología, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Martine RopertINSERM UMR 1241, Nutrition, Metabolisms and Cancer Institute (NUMECAN), AEM2 Platform, INRAE, CHU Pontchaillou, University of Rennes, 2 Rue Henri le Guilloux, 35033, Rennes, France.
Bruno TurlinINSERM UMR 1241, Nutrition, Metabolisms and Cancer Institute (NUMECAN), AEM2 Platform, INRAE, CHU Pontchaillou, University of Rennes, 2 Rue Henri le Guilloux, 35033, Rennes, France. bruno.turlin@univ-rennes1.fr.
Olivier LoréalINSERM UMR 1241, Nutrition, Metabolisms and Cancer Institute (NUMECAN), AEM2 Platform, INRAE, CHU Pontchaillou, University of Rennes, 2 Rue Henri le Guilloux, 35033, Rennes, France. olivier.loreal@univ-rennes1.fr.
Inserm · FRInstituto Nacional de Enfermedades Neoplásicas · PECentre Hospitalier Universitaire de Rennes · FRCentre National de la Recherche Scientifique · FRInstitut national de recherche en sciences et technologies du numérique · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously described a form of hepatocellular carcinoma (HCC) in non-cirrhotic liver (HCC-NC) developed by Peruvian patients. We analyzed the metallomic profile in hepatic tissues from two independent cohorts exhibiting HCC-NC. Clinical, histopathological data, and HCC and non-tumoral liver (NTL) samples of 38 Peruvian and 38 French HCC-NC patients, were studied. Twelve metals were quantified using ICP/MS: Mn, Fe, Cu, Co, Zn, As, Se, Rb, Mo, Cd, Pb, and Sn. Associations between metals and survival were assessed. Our data showed significant differences between cohorts. Mean ages were 40.6 ± 20, 67.5 ± 9 years old for Peruvians and French, respectively. Fifty percent of the Peruvian patients were positive for the HBsAg, versus 3% in French patients. Mn, Cu, Zn, As, Se, Rb, Mo, Cd, Sn metal concentrations were higher in NTL of Peruvians. Importantly, metal concentrations were lower in HCC areas compared to NTL tissues in both cohorts, except for Cu for which mean concentration was higher in HCC (p < 0.05). Se concentration in HCC was associated with extended survival only in Peruvians. Our data, obtained in Peruvian and French HCC-NC cohorts, highlights similarity in the metallomic profile of HCC compared to NTL during the hepatic tumorigenesis in these specific groups of patients.

Indexed as

AdultAgedCarcinoma, HepatocellularFemaleHumansLiverLiver NeoplasmsMaleMetalsMiddle AgedRetrospective StudiesYoung AdultMetals

Identifiers

PMID34244548
PMCPMC8271004
OpenAlexW3117368465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.